MedTrace Logo

Tolerance and Pharmacokinetics of TQ-B3233

NCT03453034 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-03-05

No results posted yet for this study

Summary

Study of Tolerance and Pharmacokinetics of TQ-B3233 Capsule, phase I,single arm.

Conditions

  • Tumor

Interventions

DRUG

TQ-B3233

QD or BID in different stage of this research

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03453034 on ClinicalTrials.gov